Results 41 to 50 of about 6,026 (204)

An Overview of Cefiderocol’s Therapeutic Potential and Underlying Resistance Mechanisms

Life, 2023
Antimicrobial resistance continues to increase globally and treatment of difficult-to-treat (DTT) infections, mostly associated with carbapenem-resistant (CR) Pseudomonas aeruginosa, CR Acinetobacter baumannii, and CR- and third-generation-cephalosporins-
Sara Domingues, Tiago Lima, Maria José Saavedra, Gabriela Jorge Da Silva   +3 more
doaj   +1 more source

Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Antibiotics, 2023
Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms.
Monirul I. Sajib, Melinda Monteforte, Roderick Go   +2 more
doaj   +1 more source

Recurrence of Postneurosurgical Central Nervous System Infection Caused by Acinetobacter baumannii in a Critically Ill Patient Treated With Cefiderocol. A Case Report [PDF]

Case Reports in Infectious Diseases
Introduction Acinetobacter baumannii (A. baumannii), a gram‐negative bacterium, has become a significant hospital pathogen and the cause of severe nosocomial infections, especially in the intensive care unit (ICU). Bacterial meningitis is a recognized complication that can occur after neurosurgery, and the number of cases of multidrug‐resistant (MDR ...
Accurso G, Ancona A, Costa G, Vitale F, Petronaci D, Corpora G, Profera L, Giarratano A, Raineri S.   +8 more
europepmc   +2 more sources

Real-life Data on Cefiderocol Efficacy and Safety to Treat Multidrug-Resistant Acinetobacter baumannii Infections [PDF]

, 2023
Background: The objective of this study was to expand real-life data on cefiderocol efficacy to treat multidrug-resistant Acinetobacter baumannii infections.
Abate, Davide Natale, Andreoni, Massimo, Ansaldo, Lorenzo, Campogiani, Laura, Celeste, Maria Grazia, Compagno, Mirko, Coppola, Luigi, Crea, Angela Maria Antonia, D'agostini, C, Iannetta, Marco, Malagnino, Vincenzo, Minardi, Maria Letizia, Pennacchiotti, Chiara, Sarmati, Loredana, Spalliera, Ilaria, Teti, Elisabetta, Vitale, Pietro   +16 more
core   +1 more source

Population Analysis of Escherichia coli Sequence Type 361 and Reduced Cefiderocol Susceptibility, France

Emerging Infectious Diseases, 2023
Cefiderocol resistance is increasingly reported in New Delhi metallo-β-lactamase–producing Enterobacterales. Genomic and phenotypic analysis of Escherichia coli sequence type 361, a primary clone causing carbapenemase spread in France, revealed ...
Agnès B. Jousset, Laura Bouabdallah, Aurélien Birer, Isabelle Rosinski-Chupin, Jean-François Mariet, Saoussen Oueslati, Cécile Emeraud, Delphine Girlich, Philippe Glaser, Thierry Naas, Rémy A. Bonnin, Laurent Dortet   +11 more
doaj   +1 more source

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae

Microbiology Spectrum, 2023
Cefiderocol and aztreonam-avibactam (ATM-AVI) both had activity against carbapenem-resistant Gram-negative bacilli, including those that produce metallo-β-lactamases (MBLs).
Yu-Shan Huang, Pao-Yu Chen, Pei-Chun Chou, Jann-Tay Wang   +3 more
doaj   +1 more source

Reduce susceptibility to cefiderocol in gram negative bacteria in children: Is hope already lost before it’s even arrived?

Journal of Infection and Public Health
Background: In last years the diffusion of carbapenem resistance in Gram-negative bacteria (CR-GNB) is increasing worldwide, mainly due to the expression of carbapenemases.
Chiara Russo, Alessio Mesini, Marcello Mariani, Elisa Tavella, Claudia Sette, Elisabetta Ugolotti, Claudia Bartalucci, Candida Palmero, Roberto Bandettini, Elio Castagnola   +9 more
doaj   +1 more source

An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients [PDF]

, 2022
open5no(1) Background: To develop evidence-based algorithms for targeted antibiotic therapy of infection-related ventilator-associated complications (IVACs) caused by non-fermenting Gram-negative pathogens.
Rossolini, G. M., Viaggi, B.
core   +4 more sources

Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii [PDF]

, 2022
Cefiderocol may represent a therapeutic option for carbapenem-resistant Acinetobacter baumannii (CRAB) infections, but clinical data are limited.
Barnini, Simona, Della Sala, Leonardo, Falcone, Marco, Farcomeni, Alessio, Leonildi, Alessandro, Menichetti, Francesco, Tiseo, Giusy, Vecchione, Alessandra   +7 more
core   +1 more source

In-Vitro Efficacy of Cefiderocol in Carbapenem-Non-Susceptible Gram-Negative Bacilli of Different Genotypes in Sub-Region of North Rhine Westphalia, Germany

Pathogens, 2021
In the last two decades, the worldwide dissemination of multidrug-resistant Gram-negative bacteria (MDR-GNB) has continued. Therapy options for such infections caused by MDR-GNB remain scarce, and only few new antimicrobial agents have been granted ...
Beniam Ghebremedhin, Parviz Ahmad-Nejad
doaj   +1 more source